CD95 and CD95L promote and protect cancer stem cells

Nature Communications

Volumn 5, Issue , 2014, Pages

  Ceppi, Paolo ^a   Hadji, Abbas ^a   Kohlhapp, Frederick J ^a   Pattanayak, Abhinandan ^a   Hau, Annika ^a   Liu, Xia ^b   Liu, Huiping ^b   Murmann, Andrea E ^a   Peter, Marcus E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; HERMES ANTIGEN; K RAS PROTEIN; MICRORNA 200; MICRORNA 200C; MICRORNA 221; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR ZEB1; FAS PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN;

APOPTOSIS; CANCER; CYTOLOGY;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL COUNT; CELL DEATH; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL KILLING; CELL PROTECTION; CONTROLLED STUDY; FEMALE; INTERNALIZATION; LOXP SITE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; HCT 116 CELL LINE; HUMAN; MCF-7 CELL LINE; METABOLISM;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; FEMALE; HCT116 CELLS; HUMANS; MCF-7 CELLS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS;

EID: 84923377209     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6238     Document Type: Article

References (49)

1. Nagata, S. Fas ligand-induced apoptosis. Annu. Rev. Genet. 33, 29-55 (1999).
2. Peter, M. E. & Krammer, P. H. The CD95(APO-1/Fas) DISC and beyond. Cell. Death Differ. 10, 26-35 (2003).
3. Kischkel, F. C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588 (1995).
4. Berke, G. Killing mechanisms of cytotoxic lymphocytes. Curr. Opin. Hematol. 4, 32-40 (1997).
5. Martin-Villalba, A., Llorens-Bobadilla, E. & Wollny, D. CD95 in cancer: tool or target? Trends Mol. Med. 19, 329-335 (2013).
6. Peter, M. E. et al. The CD95 receptor: apoptosis revisited. Cell 129, 447-450 (2007).
7. Wajant, H., Pfizenmaier, K. & Scheurich, P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 14, 53-66 (2003).
8. Desbarats, J. & Newell, M. K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6, 920-923 (2000).
9. Chen, L. et al. CD95 promotes tumour growth. Nature 465, 492-496 (2010).
10. Corsini, N. S. et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 5, 178-190 (2009).
11. Richards, M., Tan, S. P., Tan, J. H., Chan, W. K. & Bongso, A. The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 22, 51-64 (2004).
12. Hadji, A. et al. Death induced by CD95 or CD95 ligand elimination. Cell Rep. 7, 208-222 (2014).
13. Peter, M. E. DICE: a novel tumor surveillance mechanism - a new therapy for cancer? Cell Cycle 13, 1373-1378 (2014).
14. Shell, S. et al. Let-7 expression defines two differentiation stages of cancer. Proc. Natl Acad. Sci. USA 104, 11400-11405 (2007).
15. Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors, ZEB1 and ZEB2. Genes Dev. 22, 894-907 (2008).
16. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
17. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
18. Hau, A., Ceppi, P. & Peter, M. E. CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS ONE 7, e49636 (2012).
19. Peter, M. E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8, 843-852 (2009).
20. Ponti, D. et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506-5511 (2005).
21. Algeciras-Schimnich, A. et al. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc. Natl Acad. Sci. USA 100, 11445-11450 (2003).
22. Leis, O. et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31, 1354-1365 (2012).
23. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495 (2009).
24. Lee, K. H. et al. The role of receptor internalization in CD95 signaling. EMBO J. 25, 1009-1023 (2006).
25. Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273 (2009).
26. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950-7955 (2011).
27. Wu, Y. & Wu, P. Y. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18, 1127-1134 (2009).
28. Jaggupilli, A. & Elkord, E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. Immunol. 2012, 708036 (2012).
29. Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012).
30. Shmelkov, S. V. et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118, 2111-2120 (2008).
31. Visvader, J. E. & Lindeman, G. J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10, 717-728 (2012).
32. Ceppi, P. & Peter, M. E. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene 33, 269-278 (2014).
33. Brabletz, S. & Brabletz, T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep. 11, 670-677 (2010).
34. Guttilla, I. K. et al. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res. Treat. 132, 75-85 (2012).
35. Schickel, R., Park, S. M., Murmann, A. E. & Peter, M. E. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol. Cell 38, 908-915 (2010).
36. Liu, H. et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci. USA 107, 18115-18120 (2010).
37. Schmidt-Supprian, M. & Rajewsky, K. Vagaries of conditional gene targeting. Nat. Immunol. 8, 665-668 (2007).
38. Howe, E. N., Cochrane, D. R. & Richer, J. K. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J. Mammary Gland Biol. Neoplasia 17, 65-77 (2012).
39. Lu, Y. X. et al. Regulation of colorectal carcinoma stemness, growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism. Clin. Cancer. Res. 20, 2631-2642 (2014).
40. Zheng, H. et al. Glycogen synthase kinase-3 beta regulates Snail and betacatenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur. J. Cancer 49, 2734-2746 (2013).
41. Zheng, H. X. et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 32, 1183-1192 (2013).
42. Yagita, H., Seino, K., Kayagaki, N. & Okumura, K. CD95 ligand in graft rejection. Nature 379, 682 (1996).
43. Seino, K., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3, 165-170 (1997).
44. Rajesh, D. et al. Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice. Hum. Immunol. 71, 551-559 (2010).
45. Brown, B. D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457-1467 (2007).
46. Kamata, M., Liang, M., Liu, S., Nagaoka, Y. & Chen, I. S. Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs. PLoS ONE 5, e11834 (2010).
47. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
48. Aoki, K. et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol. 2, 333-337 (2001).
49. Trauth, B. C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305 (1989).